Fridbjörn Sigurdsson

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Kjell Magne Tveit, Tormod Kyrre Guren, Bengt Glimelius et al. · Journal of Clinical Oncology · 2012 · 530 citations

Medicine, Oncology, Pharmacology +16

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility

Simon Stacey, Patrick Sulem, Áslaug Jónasdóttir et al. · Nature Genetics · 2011 · 304 citations · Full text

Medicine, Genetics, Molecular Genetics +12

Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2

Sigurdís Haraldsdóttir, Wendy L. Frankel, Sylvia Einarsdottir et al. · Nature Communications · 2017 · 124 citations · Full text

Life Sciences, Genetics, Oncology +17

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

Tormod Kyrre Guren, Maria Thomsen, Elin H. Kure et al. · British Journal of Cancer · 2017 · 83 citations · Full text

Medicine, Oncology, Pharmacology +17

Granulocyte colony-stimulating factor induction of normal human bone marrow progenitors results in neutrophil-specific gene expression

Nancy Berliner, Andrew Y. Hsing, Timothy A. Graubert et al. · Blood · 1995 · 79 citations · Full text

Life Sciences, Cell Biology, Immunology +13